View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 30, 2009

GSK and Genmab Announce Positive Arthritis Drug Trial Results

GlaxoSmithKline (GSK) and Genmab have announced positive resuts from a Phase III study of ofatumumab, an intravenous treatment for patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate. The study met the primary endpoint at 24 weeks, which required a 20% o

By cms admin

GlaxoSmithKline (GSK) and Genmab have announced positive resuts from a Phase III study of ofatumumab, an intravenous treatment for patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate.

The study met the primary endpoint at 24 weeks, which required a 20% or greater improvement in the number of swollen and tender joints, as well as improvements in other disease-activity measures.

Of the 260 patients who were included in the trial, at week 24 the ACR20 response rate was significantly greater for RA patients on ofatumumab than those on placebo with a 50% response rate in the patients receiving ofatumumab, compared to 27% for patients on placebo.

GSK Biopharm Development senior vice-president Carlo Russo said that RA can be a highly debilitating disease.

“It is encouraging to see the reduction in disease symptoms achieved with intravenous ofatumumab, and we look forward to presenting the full study results,” Russo said.

There were no unexpected safety findings. However, 5% of patients experienced rash, urticaria, nasopharyngitis, pruritus, throat irritation and hypersensitivity, with these symptoms generally occurring within 24 hours of the first infusion.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology